Expiration date: 06/2026

The composition and form of issue:

Solution for intravenous and intramuscular injection of 125 mg/ml 1 ml contains:

meglumine acridonacetates in terms of greenexpo acid 125 mg

excipients: water for injections 

in ampoules of 2 ml, in a one-sided contour acheikova package 5 ampoules, contour sells packaging open or termoklina with the cover film or foil aluminum 1 contour packaging along with instructions for use and a knife for opening the ampoules or the ampoule scarifier (no points or fault lines in the ampoule) in a cardboard box.

Description pharmaceutical form:

Transparent liquid of yellow color.

Description pharmacological action:

Low-molecular inductor of interferon a wide range of biological activities (antiviral, immunomodulating, anti-inflammatory, etc.).

The main cells producing interferon after administration of Cycloferon are macrophages, T - and b-lymphocytes. Depending on the type of infection the predominant activity of a component of immune system. The drug induces high titers of interferon in organs and tissues, containing lymphoid elements (spleen, liver, lungs), activates the stem cells of the bone marrow, stimulating the formation of granulocytes. Activates T-lymphocytes and natural killer cells, normalizes the balance between subpopulations of T-helpers and T-suppressors. Passes the BBB.

Cycloferon oferon effective against viruses borne encephalitis, flu, hepatitis, herpes, CMV, HIV, HPV and other viruses. The high efficiency of the drug in the treatment of acute and chronic bacterial infections (neuroinfections, chlamydia, bronchitis, pneumonia, postoperative complications, urogenital infections, peptic ulcer disease) as a component of immunotherapy. Shows high efficacy in rheumatic and systemic diseases of connective tissue, suppressing autoimmune reactions and exerting anti-inflammatory and analgesic effects.

Indications:

Adults (in the complex therapy):

• HIV infection (AIDS stage 2A–2B)
  
• of infection (serous meningitis, encephalitis, Lyme disease)
  
• viral hepatitis (A, B, C, D)
  
• herpes and CMV infection
  
• secondary immunodeficiency States associated with acute and chronic bacterial and fungal infections
  
• rheumatic and other systemic diseases of connective tissue (rheumatoid arthritis, systemic lupus erythematosus)
  
• degenerative-dystrophic diseases of joints, including deforming osteoarthritis.
  

In children older than 4 years (in the complex therapy):

• viral hepatitis (A, B, C, D)
  
• herpes and HIV infection (stage 2A–2B).
  

Contraindications:

• hypersensitivity
  
• decompensated liver cirrhosis
  
• pregnancy
  
• lactation
  
• children up to age 4 years.
  

Side effects:

Allergic reactions.

Drug interactions:

Compatible with other drugs used in the treatment mentioned in the testimony of the diseases (interferons, chemotherapeutic drugs, etc.).

Method of application and dose:

In/m. Adults: 1 time per day for basic scheme on 1, 2, 4, 6, 8, 11, 14, 17, 20, 23, 26, 29 day depending on the disease.

Viral hepatitis: a single dose of 0.25–0.5 g. Course of treatment — 10 injections at the base scheme. Total dose — 2,5–5 g. a second course in 10-14 days.

Herpes and CMV infection in the base schema 10 injection of 0.25 g. the total dose of 2.5 g. Treatment is most effective early in the exacerbation.

Neuroinfections — base schema. The course of treatment — 12 injections of 0,25–0,5 g in combination with etiotropic therapy. Cumulative dose — 3-6 g. Repeated courses as necessary.

Chlamydial infection according to the base scheme. The course of treatment — 10 injections of 0,25 g. a total dose of 2.5 g, a second course in 10-14 days. Appropriate combination of Cycloferon with antibiotics.

HIV infection (AIDS stage 2A–2B) — 10/m injection according to the basic scheme in a single dose 0.5 g. the total dose — 5 g. Next is support rate: 1 every 5 days for 2.5 months, a second course is prescribed after 1 month.

Immunodeficiency States — 10 V/m injection at the base scheme at a dose of 0.25 g. the total dose — 2,5 g, repeated courses are held in 6-12 months.

Rheumatic and systemic diseases of connective tissue — 4 courses of 5 injections of 0.25 g in the basic scheme, with an interval of 10-14 days. A second course on the recommendation of a physician.

Degenerative-dystrophic diseases of joints — 2 courses of 5 injections of 0.25 g with an interval 10-14 days for the basic scheme. A second course on the recommendation of a physician.

Children in/m or/in 1 times a day, the daily dose from the calculation of 6-10 mg/kg. In the basic scheme through the day.

Acute viral hepatitis (A, B, C, D, and mixed forms) — drug is injected at the base schema 15 injections. When protracted course, the repetition rate in 10-14 days.

Chronic viral hepatitis (B, C, D) — drug is injected at the base schema 10 injection, and further for supporting the scheme 3 times a week for 3 months in the combined therapy. Recommended in combination with interferons and chemotherapy.

HIV infection (stage 2A–2B) is a course of 10 injections at the base scheme and further supporting the scheme: 1 every 3 days for 3 months. A repeated course in 10 days.

Herpes infection — a course of 10 injections at the base scheme. While maintaining the replicative activity of the virus, the treatment is continued support for the scheme: 1 every 5 days for 4 weeks.

Precautions:

In diseases of the thyroid treatment should be under the control of the endocrinologist.

Special instructions:

The freezing of the solution in the process of transportation at negative temperatures does not change the properties of the drug. Thawed at room temperature the product retains their biological and physico-chemical properties. If you change the color of the solution and precipitate the use of the drug is unacceptable.

Storage conditions:

The freezing of the solution in the process of transportation at negative temperatures does not change the properties of the drug. Thawed at room temperature the drug sohranyaet their biological and physico-chemical properties. If you change the color of the solution and precipitate the use of the drug is unacceptable.